Education & Training

 

AGA Education, Practice and Research

Focused Clincial Updates 2006

To receive full CME credit, you are required to complete the evaluation form and self-test for each chapter you complete. Upon completion of the evaluation form and test, a certificate with your name and number of credits you have claimed will be generated. You must print your certificate using the print function in your browser.

The objectives listed below are to be used when evaluating the program. After completing this program, each participant should be able to:

  • Identify how state of the art and emerging research will impact management of digestive conditions.
  • Review diagnostic and treatment options for patients with several digestive diseases.

 

Treatment of Functional Bowel Disorders

Select one answer for each question. You may change your answers as many times as you need to until you click the "Submit" button located at the bottom of the test.

1. Rifaximin was compared to placebo in a double-blind, randomized, controlled study. The findings were as follows:

Rifaxim was no different than placebo at all time points

At the end of 10 weeks, bloating, diarrhea, abdominal pain and constipation were all improved on Rifaximin versus placebo

Diarrhea improved but not bloating

Placebo was superior to Rifaximin in symptom improvement

2. With regards to other treatments for constipation predominant irritable bowel syndrome, the following are correct:

Lubiprostone improved abdominal pain compared to placebo at months one, two, and three in patients with constipation predominant IBS

Lubiprostone improved abdominal pain at months one and two, but not three

The improvement was not dose-related

None of the above are correct

3. Which of the following are correct?

Lipase supplementation resulted in short-term improvement in stomach fullness in patients with non-ulcer dyspepsia

The probiotic organism Bifidobacterium infantis 35624 is extremely safe after one year of use in inflammatory bowel disease

Mesalamine 800 mg twice daily was reported superior to Rifaximin in improvement of abdominal pain and bloating in patients with symptomatic diverticular disease

All are correct

4. With regard to treatment of moderate to severe irritable bowel syndrome:

Cognitive behavoiral therapy is not superior to a so-called waiting list for therapy in symptom improvement

Male patients are more likely to discontinue tricyclic antidepressants in functional GI disorders

Peppermint oil was unsuccessful in improvement of any symptom of IBS

Both estradiol and combination estradiol and progesterone accelerated gastrointestinal transit in post menopausal women